Hims & Hers Health short interest was 37.85% of the float on April 15th, according to new data we received from Benzinga. Short interest totaled 69,774,819 shares, which was a decrease of -2.22% from March 31st.
It is estimated that it would take 3.01 days for short sellers to buy back their shares, with current trading volumes.
Hims & Hers Health Hedge Fund Activity
We have seen 226 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 310 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FORERUNNER VENTURES MANAGEMENT, LLC removed 9,756,893 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $316,806,315
- FARALLON CAPITAL MANAGEMENT LLC removed 7,359,866 shares (-68.5%) from their portfolio in Q4 2025, for an estimated $238,974,849
- CAPITAL WORLD INVESTORS removed 4,460,282 shares (-23.7%) from their portfolio in Q4 2025, for an estimated $144,825,356
- RENAISSANCE TECHNOLOGIES LLC removed 4,278,843 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $138,934,032
- MORGAN STANLEY removed 3,346,864 shares (-46.0%) from their portfolio in Q4 2025, for an estimated $108,672,674
- TIDAL INVESTMENTS LLC removed 2,759,789 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $89,610,348
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,341,642 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $76,033,115
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 157,440 shares for an estimated $4,743,270.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,039 shares for an estimated $2,906,827.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 6 sales selling 26,831 shares for an estimated $810,369.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 13,940 shares for an estimated $445,278.
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 10,021 shares for an estimated $367,870
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Underperform" rating on 11/04/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 12 analysts offer price targets for $HIMS in the last 6 months, with a median target of $26.5.
Here are some recent targets:
- Allen Lutz from B of A Securities set a target price of $32.0 on 04/24/2026
- Cory Carpenter from JP Morgan set a target price of $35.0 on 04/24/2026
- Jonna Kim from TD Cowen set a target price of $23.0 on 03/27/2026
- Michael Cherny from Leerink Partners set a target price of $25.0 on 03/16/2026
- Glen Santangelo from Barclays set a target price of $29.0 on 03/11/2026
- George Hill from Deutsche Bank set a target price of $28.0 on 03/10/2026
- Daniel Grosslight from Citigroup set a target price of $24.0 on 03/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
